May 30, 2013
Regtect Tablets 333 mg Nippon Shinyaku on May 27 launched Regtect Tablets 333 mg (acamprosate calcium) for supporting maintenance of abstinence in patients with alcohol dependence. Regtect is Japan’s first drug that suppresses the desire to drink alcohol by affecting...read more